WO2008086449A3 - Synthetic osteopontin peptides and methods of use - Google Patents

Synthetic osteopontin peptides and methods of use Download PDF

Info

Publication number
WO2008086449A3
WO2008086449A3 PCT/US2008/050678 US2008050678W WO2008086449A3 WO 2008086449 A3 WO2008086449 A3 WO 2008086449A3 US 2008050678 W US2008050678 W US 2008050678W WO 2008086449 A3 WO2008086449 A3 WO 2008086449A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
osteopontin
synthetic
treatment
disclosed
Prior art date
Application number
PCT/US2008/050678
Other languages
French (fr)
Other versions
WO2008086449A2 (en
WO2008086449A8 (en
Inventor
Mary Stenzel-Poore
Susan Stevens
Kristian Doyle
Original Assignee
Univ Oregon Health & Science
Mary Stenzel-Poore
Susan Stevens
Kristian Doyle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science, Mary Stenzel-Poore, Susan Stevens, Kristian Doyle filed Critical Univ Oregon Health & Science
Publication of WO2008086449A2 publication Critical patent/WO2008086449A2/en
Publication of WO2008086449A3 publication Critical patent/WO2008086449A3/en
Publication of WO2008086449A8 publication Critical patent/WO2008086449A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This disclosure relates to the field of neurology. More specifically, disclosed herein are several osteopontin mimetic peptides that are useful for the treatment of stroke and other ischemic injuries. Also disclosed are methods for the treatment of cellular damage due to excitotoxic injury, ischemia, and/or hypoxia by administering an osteopontin peptide mimetic.
PCT/US2008/050678 2007-01-09 2008-01-09 Synthetic osteopontin peptides and methods of use WO2008086449A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87964507P 2007-01-09 2007-01-09
US60/879,645 2007-01-09

Publications (3)

Publication Number Publication Date
WO2008086449A2 WO2008086449A2 (en) 2008-07-17
WO2008086449A3 true WO2008086449A3 (en) 2008-10-09
WO2008086449A8 WO2008086449A8 (en) 2009-08-06

Family

ID=39581858

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/050678 WO2008086449A2 (en) 2007-01-09 2008-01-09 Synthetic osteopontin peptides and methods of use

Country Status (1)

Country Link
WO (1) WO2008086449A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2493540A (en) * 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
GB201406989D0 (en) * 2014-04-17 2014-06-04 Follicum Ab Novel treatments
JP2020518556A (en) 2017-05-04 2020-06-25 フォリクム エービー Peptides for the treatment of diabetes
WO2019036331A1 (en) * 2017-08-15 2019-02-21 The Children's Medical Center Corporation Osteopontin as a treatment for neuronal lesions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001071358A1 (en) * 2000-03-23 2001-09-27 Glaxo Group Limited Method of screening for inhibitors of osteopontin
WO2002092122A2 (en) * 2001-05-17 2002-11-21 Applied Research Systems Ars Holding N.V. Use of osteopontin for the treatment and/or prevention of neurologic diseases
WO2006087579A1 (en) * 2005-02-18 2006-08-24 Proximagen Ltd. Treatment for neurodegeneration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001071358A1 (en) * 2000-03-23 2001-09-27 Glaxo Group Limited Method of screening for inhibitors of osteopontin
WO2002092122A2 (en) * 2001-05-17 2002-11-21 Applied Research Systems Ars Holding N.V. Use of osteopontin for the treatment and/or prevention of neurologic diseases
WO2006087579A1 (en) * 2005-02-18 2006-08-24 Proximagen Ltd. Treatment for neurodegeneration

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DOYLE KRISTIAN P ET AL: "Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke.", JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM : OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF CEREBRAL BLOOD FLOW AND METABOLISM JUN 2008, vol. 28, no. 6, June 2008 (2008-06-01), pages 1235 - 1248, XP009103018, ISSN: 0271-678X *
GREEN P M ET AL: "Structural elements of the osteopontin SVVYGLR motif important for the interaction with alpha4 integrins", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 503, no. 1, 10 August 2001 (2001-08-10), pages 75 - 79, XP004350240, ISSN: 0014-5793 *
HWANG SHIAW-MIN ET AL: "Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 1, 1994, pages 711 - 715, XP002488345, ISSN: 0021-9258 *
LOFTUS ET AL: "In vivo protein transduction to the CNS", NEUROSCIENCE, NEW YORK, NY, US, vol. 139, no. 3, 1 January 2006 (2006-01-01), pages 1061 - 1067, XP005415062, ISSN: 0306-4522 *
MELLER ROBERT ET AL: "Neuroprotection by osteopontin in stroke", JOURNAL OF CEREBRAL BLOOD FLOW & METABOLISM, vol. 25, no. 2, February 2005 (2005-02-01), pages 217 - 225, XP009103017, ISSN: 0271-678X *
PARDRIDGE ET AL: "Blood-brain barrier delivery", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 12, no. 1-2, 30 December 2006 (2006-12-30), pages 54 - 61, XP005819183, ISSN: 1359-6446 *
YAMAMOTO N ET AL: "Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 112, 1 July 2003 (2003-07-01), pages 181 - 188, XP003021585, ISSN: 0021-9738 *
YOKOSAKI Y ET AL: "THE INTEGRIN ALPH9BETA1 BINDS TO A NOVEL RECOGNITION SEQUENCE (SVVYGLR) IN THE THROMBIN-CLEAVED AMINO-TERMINAL FRAGMENT OF OSTEOPONTIN", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 274, no. 51, 17 December 1999 (1999-12-17), pages 36328 - 36334, XP002953833, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2008086449A2 (en) 2008-07-17
WO2008086449A8 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
IL261900A (en) Humanized antibodies against liv-1, compositions comprising the same and uses thereof
LTPA2017029I1 (en) Recombinant FSH including alpha 2,3- and alpha-2,6-sialylation
IL204607A (en) Antibodies against osteoclast- related protein siglec-15, compositions comprising the same and uses thereof
WO2014144791A3 (en) Therapeutic peptides
WO2012177444A3 (en) Glucagon/glp-1 receptor co-agonists
WO2012177443A3 (en) Glucagon/glp-1 receptor co-agonists
WO2011160630A3 (en) Glucagon analogues
WO2014052647A3 (en) Proline-locked stapled peptides and uses thereof
WO2007011739A3 (en) Polymers with low band gaps and high charge mobility
MY177564A (en) Anti-nr10 antibody and use thereof
WO2012047427A3 (en) Antibodies for botulinum neurotoxins
MX347829B (en) Multivalent antigen-binding fv molecule.
WO2018053180A3 (en) Proximity-based sortase-mediated protein purification and ligation
WO2008093058A3 (en) Peptides and their use
WO2015075269A9 (en) Antibodies against ccr9 and applications thereof
WO2008086449A3 (en) Synthetic osteopontin peptides and methods of use
WO2013143935A3 (en) Dry shampoo composition
CL2012002378A1 (en) Method for producing soluble recombinant interferon type 1 proteins without denaturation.
SG10201803999UA (en) Recombinant factor viii formulations
HK1151733A1 (en) Antigen-and-drug vehicle comprising synthetic peptide, and mucosal vaccine using the same
WO2010034825A3 (en) Novel antibodies recognizing native annexin a3
WO2015071573A3 (en) Device for fastening a vehicle to a drive device of a transport line
ITUA20161610A1 (en) PHARMACOLOGICALLY ACTIVE PEPTIDIC COMPOUND, PROCEDURE FOR ITS PREPARATION AND ITS USE.
WO2012088397A3 (en) Cyclic crf antagonist peptides
TH76271S1 (en) Roof carrier bar

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08727490

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08727490

Country of ref document: EP

Kind code of ref document: A2